6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Salud sexual en mujeres con cáncer de mama tratadas con Tamoxifeno Translated title: Sexual health in women with breast cancer treated with Tamoxifen

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen El cáncer de mama puede alterar ciertos componentes de la función sexual debidos a la enfermedad y los tratamientos empleados en su abordaje. Objetivo. Analizar si las pacientes con cáncer de mama en tratamiento con Tamoxifeno presentan disfunción sexual. Método. Estudio transversal, observacional para detectar disfunción sexual en pacientes con cáncer de mama en tratamiento con Tamoxifeno y comparar los resultados con población general. Se han analizado los casos de cáncer de mama diagnosticados en el Hospital Virgen de la Luz de abril de 2015 a abril 2016, seleccionando mujeres en tratamiento con Tamoxifeno, menores de 50 años y sexualmente activas, aplicándoseles un cuestionario de salud sexual, posteriormente se compararon los resultados obtenidos con un estudio realizado en población general. Resultados. Se diagnosticaron 130 cánceres de mama en dicho periodo, siendo 34 susceptibles de estudio (26,15 %). Participaron 7 pacientes (20.6%), con edad media de 42,7 años (35-50) y pareja estable en el 85,7%. Se han objetivado trastornos moderados del deseo sexual en un 28,6% y de excitación en 14,28%, así como ausencia de iniciativa sexual en un 42,86%, trastorno de la lubricación vaginal en un 28,6% y problemas para la penetración vaginal en un 14,3 %, pero globalmente están satisfechas con su actividad sexual. Comparando con población general, llama la atención que un 14,2 % de éstas últimas muestra algún grado de insatisfacción sexual. Conclusiones. No hay diferencias significativas en cuanto a disfunción sexual, aunque puede haber mayor ansiedad anticipatoria y disfunción del deseo sexual y lubricación vaginal en el grupo de Tamoxifeno, que probablemente no alcanzan la significación estadística por el tamaño muestral.

          Translated abstract

          Abstract Breast cancer can alter certain components of sexual function due to the disease and the treatments used. Objetive. To analyze if patients with breast cancer treated with Tamoxifen have sexual dysfuntion. Method. Cross-sectional, observational study to detect sexual dysfunction in patients with breast cancer with Tamoxifen treatment and compare it with general population. The cases of breast cancer at Virgen de La Luz Hospital from April 2015 to April 2016 have been analyzed, selecting women in treatment with tamoxifen, under 50 years and sexually active, applying a sexual health questionnarie and comparing them with general population. Results. 130 breast cancers were diagnosed, 34 were susceptible to study (26,15%). Seven patients (20,6%) participated, with a mean age of 42,7 years (35-50) and stable partner in 85,7%. Moderate disorders of sexual desire have been observed in 28,6% and in arousal in 14,28%, as well as lack of sexual initiative in 42,86%, disorder of vaginal lubrication in 28,6% and problems with vaginal penetration in 14,3%, but overall they are satisfied with their sexual activity. Comparing with general population, it´s striking that 14,2% of the last show some degree of sexual insatisfaction. Conclusions. There are no significant differences regarding sexual dysfunction, although there may be greater anticipatory anxiety, sexual desire dysfunction and vaginal lubrication in the Tamoxifen group, which probably do not reach statistical significance due to sample size.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Breast cancer treatment and sexual dysfunction: Moroccan women's perception

          Background This exploratory prospective study evaluated women's responses to questions that asked them to describe how their body image and sexual functioning had changed since their breast cancer diagnosis to treatment. Methods A questionnaire concerning body image scale and various sexual problems experienced after diagnosis and treatment was anonymously completed by 120 women in the outpatient clinic of our hospital's Division of medical Oncology. To be eligible, subjects had to be sexually active and had histology proven breast cancer. They also had to have received treatment for breast cancer. Results 100% of participants have never spoken with their doctor about this subject. 84% of the participants continued sexual activity after treatment, but there was an increase in the incidence of sexual functioning problems which resulted in a slight reduction in the quality of their sex lives. 65% of the women experienced dyspareunia followed by lubrication difficulties (54%) and the absence or reduction of sexual desire (48% and 64%, respectively) while, 37% had lack of satisfaction (37%). Female orgasmic disorder and brief intercourse and arousal were reported respectively by 40% and 38% of the subjects. The sexual dysfunctions were absent before diagnosis and management of breast cancer in 91.5% subjects and of these 100% subjects complained of a deterioration of the symptomatology after the various treatments. 90% of the dysfunctions were observed after chemotherapy, 9% after surgery and 3% after radiotherapy; none of the subjects indicated the onset of dysfunctions to have been associated with hormonotherapy. 100% expressed not having received sufficient information about how the disease and treatment (including surgery) might affect their sexual life. Conclusion Breast cancer and its treatment may result in significant difficulties with sexual functioning and sexual life. Addressing these problems is essential to improve the quality of life of Moroccan women with breast cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Investigating Sexual Function and Affecting Factors in Women with Breast Cancer in Iran.

            Since the breast is strongly relevant to sexual desire, and physical and sexual attractiveness, the high prevalence of breast cancer (BC) in Iran and longterm survival of patients experiencing side effects means that measures to identify associated sexual problems are necessary. Therefore, this study was conducted to assess sexual function and affecting factors in women with BC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.

              For the hundreds of thousands of premenopausal women who are diagnosed annually with endocrine-sensitive breast cancer, treatment strategies are complex. For many, chemotherapy may not be necessary, and endocrine therapy decision making is paramount. Options for adjuvant endocrine regimens include tamoxifen for 5 years, tamoxifen for 10 years, ovarian function suppression (OFS) plus tamoxifen for 5 years, and OFS plus an aromatase inhibitor for 5 years. There are modest differences in efficacy between these regimens, with a benefit from OFS most obvious among patients with higher-risk disease; therefore, choosing which should be used for a given patient requires consideration of expected toxicities and patient preferences. An aromatase inhibitor cannot be safely prescribed without OFS in this setting. Additional research is needed to determine whether genomic tests such as Prosigna and Endopredict can help with decision making about optimal duration of endocrine therapy for premenopausal patients. Endocrine therapy side effects can include hot flashes, sexual dysfunction, osteoporosis, and infertility, all of which may impair quality of life and can encourage nonadherence with treatment. Ovarian function suppression worsens menopausal side effects. Hot flashes tend to be worse with tamoxifen/OFS, whereas sexual dysfunction and osteoporosis tend to be worse with aromatase inhibitors/OFS. Pregnancy is safe after endocrine therapy, and some survivors can conceive naturally. Still, embryo or oocyte cryopreservation should be considered at the time of diagnosis for patients with endocrine-sensitive disease who desire future childbearing, particularly if they will undergo chemotherapy.
                Bookmark

                Author and article information

                Journal
                jonnpr
                Journal of Negative and No Positive Results
                JONNPR
                Research and Science S.L. (Madrid, Madrid, Spain )
                2529-850X
                2020
                : 5
                : 12
                : 1528-1537
                Affiliations
                [1] Albacete orgnameComplejo Hospitalario Universitario España
                [2] orgnameGerencia de Atención Integrada de Albacete. España
                [3] Cuenca orgnameHospital Virgen de la Luz Spain
                Article
                S2529-850X2020001200007 S2529-850X(20)00501200007
                10.19230/jonnpr.3982
                b33be1d2-9e77-412b-85a6-8216941537a1

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

                History
                : 04 September 2020
                : 10 October 2020
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 5, Pages: 10
                Product

                SciELO Spain

                Categories
                Original

                Tamoxifen,Breast,SERM,Sexuality,Salud sexual,Tamoxifeno,Cáncer de Mama,sexualidad,mama,Sexual Health,Women,Breast Cancer

                Comments

                Comment on this article